MiNK Therapeutics (INKT)
NASDAQ:INKT
Want to see INKT full AI Analyst Report?
Earnings Data
Report Date
May 13, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.7Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed multiple substantive clinical and translational wins (durable oncology responses, strong ARDS signals, initiation of randomized pulmonary and GvHD programs), meaningful nondilutive funding and improved capital efficiency (cash up ~191%, operating costs down ~40%). However, the company remains early‑stage with ongoing net losses (FY loss up ~16%), a limited runway extended only through 2026, and some program timing and partnership uncertainties. On balance the strength of the clinical data, funding traction and disciplined cost reduction outweigh near‑term financial and operational risks.Company Guidance
Strong clinical activity and durability in oncology
MiNK reported durable clinical responses in heavily pretreated, checkpoint-refractory solid tumors: median overall survival exceeding 23 months in combination with PD-1 therapies, and complete remissions extending beyond 2 years across multiple tumor types (gastric, thymoma, renal, adenoid cystic, lung). These data support mechanism-of-action observations including activation/expansion of dendritic cells, macrophage repolarization, and reinvigoration of exhausted T cells with controlled cytokine increases (IFN-γ, IL-2, TNF-α) and favorable safety.
Compelling Phase I/II pulmonary (ARDS) signals
Phase I/II results in hypoxemic pneumonia/ARDS showed strong signals: dosing up to 1 billion MiNK cells was well tolerated with no cytokine release, dampening of harmful pro-inflammatory signals, improved oxygenation and endothelial lung function, rapid clinical improvement (patients coming off VV-ECMO), pathogen clearance and reduction in secondary infections. Survival in treated patients was ~70% versus ~10% in hospital controls (approximately a 7x relative improvement).
Advancing randomized Phase II ARDS and GvHD programs
MiNK is initiating a MiNK-sponsored randomized Phase II (with expansion to Phase II/III) in ARDS/hypoxemic pneumonia imminently, with initial clinical data expected in H2 2026. The GvHD trial is in activation at University of Wisconsin with clinical initiation targeted in H1 2026 and is supported by nondilutive funding.
Capital efficiency and improved financial position
Year-end cash increased to $13.4 million from $4.6 million (increase of ~$8.8M, ~191% year‑over‑year), and operating costs decreased nearly 40% over 2025. Since year-end the company raised an additional $3.0 million via its ATM program, extending runway through 2026.
Nondilutive funding and strategic collaborations
Company secured multiple nondilutive funding sources in 2025 (NIH NIAID STTR award, Mary Gooze Clinical Trial Award, philanthropic support and consortium funding via C‑Further including >$1M for IND‑enabling work). C‑Further collaboration advances a PRAME-targeted iNKT TCR program and preserves meaningful downstream economics and nonexclusive, capital‑efficient partnerships.
Pipeline progress and upcoming data/communications
MiNK continues to advance next‑gen programs (PRAME TCR iNKT and MiNK‑215 CAR iNKT). MiNK‑215 IND‑enabling progress and translational updates are expected with announcements in the next 3–5 months; second‑line gastric cancer efficacy data are expected at a major conference in H1 2026. Multiple peer‑reviewed publications and data presentations anticipated in H1 2026.
Operational and leadership improvements
MiNK emphasized manufacturing scale and 'off‑the‑shelf' advantages (no lymphodepletion or HLA matching) enabling community hospital administration. The company appointed Melissa Orilall as Principal Financial and Accounting Officer to strengthen financial operations and capital allocation.
INKT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INKT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 31, 2026 | $10.52 | $10.53 | +0.10% |
Nov 14, 2025 | $13.22 | $12.75 | -3.56% |
Aug 14, 2025 | $17.50 | $15.32 | -12.46% |
May 15, 2025 | $7.50 | $7.18 | -4.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MiNK Therapeutics (INKT) report earnings?
MiNK Therapeutics (INKT) is schdueled to report earning on May 13, 2026, Before Open (Confirmed).
What is MiNK Therapeutics (INKT) earnings time?
MiNK Therapeutics (INKT) earnings time is at May 13, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INKT EPS forecast?
Currently, no data Available